Rxsight Inc

RXST remains locked in a Stage 4 decline with a persistent sequence of lower highs and lower lows, trading below the 50 DMA and 200 DMA. The recent bounce above the 9 EMA/21 EMA offers a clean speculative sell entry in line with the dominant downtrend. No primary patterns support a bullish reversal, so execution should capitalize on resumed weakness while respecting resistance zones. A close above key moving averages would invalidate this bearish posture.

• ↑Proprietary LAL platform uniquely differentiates RxSight in premium IOL market
• ↑Q1 gross margin rose to 76.1% from 74.8% YoY, reflecting improved product mix
• ↓Q1 2026 sales declined 18% YoY to $30.9M, signaling demand weakness